• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LI Jingjing, TAN Jingfu, YANG Jie, WANG Qiang. Pharmacokinetic study of corosolic acid in normal rats and diabetic rats by LC-MS[J]. Journal of China Pharmaceutical University, 2014, 45(1): 84-87. DOI: 10.11665/j.issn.1000-5048.20140115
Citation: LI Jingjing, TAN Jingfu, YANG Jie, WANG Qiang. Pharmacokinetic study of corosolic acid in normal rats and diabetic rats by LC-MS[J]. Journal of China Pharmaceutical University, 2014, 45(1): 84-87. DOI: 10.11665/j.issn.1000-5048.20140115
shu

Pharmacokinetic study of corosolic acid in normal rats and diabetic rats by LC-MS

More Information
    Graphical Abstract
    • Abstract
  • An LC-MS method for quantification of corosolic acid in the plasma of rats was developed to investigated the pharmacokinetics of corosolic acid in normal and diabetic rats. Corosolic acid(170 mg/kg)was orally administered to normal rats and the diabetic rats induced by streptozotocin respectively. Blood samples were obtained from the oculic horioideae vein before and after dosing at selected intervals. The concentrations of corosolic acid were determined by LC-MS and the concentration-time data were analyzed by non-compartmental method using DAS 2. 0 software. Doublet peaks were shown in both normal and diabetic rats. The cmax and AUC0-24 h were significantly increased, t1/2 was remarkably prolonged and CL/F was observably decreased compared with those in the normal rats. The status of diabetes mellitus could alter the pharmacokinetics of corosolic acid in rats. The result obtained from the present study could provide reference for the evaluation of its relevant clinical efficacy.
    • FullText(HTML)
    • References (12)
  • [1]
    Shaw JE,Sicree RA,Zimmet PZ.Global estimates of the prevalence of diabetes for 2010 and 2030[J].Diabetes Res Clin Pract,2010,87(1):4-14.
    [2]
    Engelgau MM,Geiss LS,Saaddine JB,et al.The evolving diabetes burden in the United States[J].Ann Intern Med,2004,140(11):945-950.
    [3]
    Kudo T,Shimada T,Toda T,et al.Altered expression of CYP in TSOD mice:a model of type 2 diabetes and obesity[J].Xenobiotica,2009,39(12):889-902.
    [4]
    Kim YC,Oh EY,Kim SH,et al.Pharmacokinetics and pharmacodynamics of intravenous to rasemide in diabetic ratsinduced by alloxan or streptozotocin[J].Biopharm Drug Dispos,2005,26(8):371-378.
    [5]
    Miura T,Ueda N,Yamada K,et al.Antidiabetic effects of corosolic acid in KK-Ay diabetic mice[J].Biol Pharm Bull,2006,29(3):585-587.
    [6]
    Srinivasan K,Viswanad B,Asrat L,et al.Combination of high-fat diet-fed and low-dose streptozotocin-treated rat:a model for type 2 diabetes and pharmacological screening[J].Pharmacol Res,2005,52(4):313-320.
    [7]
    Liu Q,Zhao D,Chen X,et al.Determination of corosolic acid,a natural potential anti-diabetes compound in rat plasma by high-performance liquid chromatography-mass spectrometry and its application to pharmacokinetic and bioavailability studies[J].Planta Med,2011,77(15):1 707-1 711.
    [8]
    Lehr T,Staab A,Tillmann C,et al.A quantitative enterohepatic circulation model:development and evaluation with tesofensine and meloxicam[J].Clin Pharmacokinet,2009,48(8):529-542.
    [9]
    Salgin B,Ong KK,Thankamony A,et al.Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes[J].J Clin Endocrinol Metab,2012,97(9):3 302-3 309.
    [10]
    CohenMP,Ziyadeh FN,Chen S.Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes:pathogenic and therapeutic implications[J].J Lab Clin Med,2006,147(5):211-219.
    [11]
    Prashanth M,Ganesh HK,Vima MV,et al.Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J].J Assoc Physicians India,2009,57:205-210.
    [12]
    Zhuo L,Zou G,Li W,et al.Prevalence of diabetic nephropathy complicating non-diabetic renal disease among Chinese patients with type 2 diabetes mellitus[J].Eur J Med Res.2013,18(1): 4-11.
    • Related Articles

  • Related Articles

    [1]LI Xueyan, CHEN Na, JIANG Cheng. Research progress of KRAS inhibitors[J]. Journal of China Pharmaceutical University, 2024, 55(2): 257-269. DOI: 10.11665/j.issn.1000-5048.2024010801
    [2]YANG Wanwan, YE Fangyu, WU Yujia, WANG Haochen, ZHAO Li. Research progress of PARP inhibitors in cancers and their drug resistance[J]. Journal of China Pharmaceutical University, 2022, 53(5): 525-534. DOI: 10.11665/j.issn.1000-5048.20220503
    [3]YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
    [4]ZHAN Kangning, QUAN Xu, HUANG Zhangjian, ZHAO Liwen. Research progress of protein arginine methyltransferase 5 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(3): 371-378. DOI: 10.11665/j.issn.1000-5048.20210315
    [5]LI Zhiyan, LIU Jie, LI Bingyan, JIANG Cheng. Design, synthesis and evaluation of peptidomimetics targeting the polo-box domain of polo-like kinase 1[J]. Journal of China Pharmaceutical University, 2020, 51(3): 287-294. DOI: 10.11665/j.issn.1000-5048.20200305
    [6]LIANG Tingting, WANG Wenjie, HE Guangchao, HE Guangchao, XU Yungen. Research progress of ERK small molecule inhibitors[J]. Journal of China Pharmaceutical University, 2020, 51(3): 260-269. DOI: 10.11665/j.issn.1000-5048.20200302
    [7]SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
    [8]WANG Tianshuai, YU Junjie, ZHANG Yan, ZENG Jinjin, CUI Jingxin. Advances in platinum-intercalators of DNA as antitumor agents[J]. Journal of China Pharmaceutical University, 2019, 50(5): 505-515. DOI: 10.11665/j.issn.1000-5048.20190501
    [9]GUO Yahui, LU Peng, WANG Yubin, ZHANG Huibin. Progress in the researches for antitumor NEDD8 activating enzyme inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 646-653. DOI: 10.11665/j.issn.1000-5048.20170603
    [10]KONG Kai-lai, LU Shuai, GAO Yi-ping, YANG Pei, TANG Wei-fang, LU Tao. Advances on the study of PLK1 inhibitors as antitumor agents[J]. Journal of China Pharmaceutical University, 2011, 42(1): 9-15.

Catalog

    Get Citation
    PDF
    XML
    Article views (1439) PDF downloads (1869) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：302646

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return